EUVIMEDEUVIMED entdecken
Crossref

Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with In Vitro and In Vivo Efficacy against Triple-Negative Breast Cancer

Dehua Lu, Weiping Lyu, Xiaowei Chi, Qi Li, Yiran Zhou, Bin Lu, Xiangyu Zhang, Xiaojiao Sun, Zhiqi Wang, Siyu Xiu iD, Tingting Yang, Zhongwei Wang und 7 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c01080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Dehua Lu und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors, Receptor Tyrosine Kinase-like Orphan Receptors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality, State Key Laboratory of Pharmaceutical Biotechnology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a kind of pseudokinase, although ROR1 lacks the ATP catalytic activity similar to that of classical kinases, it has been proven to play a crucial role in the occurrence and development of triple-negative breast cancer (TNBC). Through structure-based drug design strategy, we have discovered novel quinolin-2-amine ROR1 inhibitor 59 which exhibited excellent binding activity to ROR1 (KD = 0.052 μM) and antiproliferative against breast cancer cells in vitro (IC50 = 0.075 μM) while maintaining good selectivity through kinase profiling screening. Mechanistic studies confirmed 59 could induce cell apoptosis and suppresses ROR1 phosphorylation. In vivo experiments in mice have demonstrated that compound 59 could significantly inhibit the growth (TGI = 92.1% at 20 mg/kg) and metastasis of tumors, moreover 59 showed no significant toxicity. Although the oral bioavailability is relatively low, the overall results confirm that compound 59 can serve as a potential candidate for the treatment of TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntineoplastic AgentsProtein Kinase InhibitorsReceptor Tyrosine Kinase-like Orphan ReceptorsHumansAnimalsFemaleStructure-Activity RelationshipMiceApoptosisCell ProliferationCell Line, TumorDrug DiscoveryMolecular Docking SimulationXenograft Model Antitumor AssaysDrug Screening Assays, AntitumorMice, NudeMice, Inbred BALB C

Substanzen

Antineoplastic AgentsProtein Kinase InhibitorsROR1 protein, humanReceptor Tyrosine Kinase-like Orphan Receptors

Autor:innen und Institutionen

  • State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
  • key Laboratory of Xinjiang Endemic Phytomedicine Resources Ministry of Education; School of Pharmacy, Shihezi University, Shihezi 832003, Xinjiang, China.

ORCID-Profile: Siyu Xiu, Cheng Shi, Song Song, Liangren Zhang, Zhenming Liu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality
  • State Key Laboratory of Pharmaceutical Biotechnology

Zitieren

APA

Lu, D., Lyu, W., Chi, X., Li, Q., Zhou, Y., Lu, B., Zhang, X., Sun, X., Wang, Z., Xiu, S., Yang, T., Wang, Z., Zheng, R., Zhou, J., Chen, Y., Shi, C., Song, S., Zhang, L., & Liu, Z. (2025). Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with In Vitro and In Vivo Efficacy against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01080

Vancouver

Lu D, Lyu W, Chi X, Li Q, Zhou Y, Lu B, et al. Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with In Vitro and In Vivo Efficacy against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01080

BibTeX
@article{Lu2025,
  author = {Lu, Dehua and Lyu, Weiping and Chi, Xiaowei and Li, Qi and Zhou, Yiran and Lu, Bin and Zhang, Xiangyu and Sun, Xiaojiao and Wang, Zhiqi and Xiu, Siyu and Yang, Tingting and Wang, Zhongwei and Zheng, Ruqiu and Zhou, Jiaxu and Chen, Yanming and Shi, Cheng and Song, Song and Zhang, Liangren and Liu, Zhenming},
  title = {Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with In Vitro and In Vivo Efficacy against Triple-Negative Breast Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c01080}
}
Kostenlos starten →